Publicaciones (33) Publicaciones de Marta Zalacain Díez

2024

  1. The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models

    Neuro-Oncology, Vol. 26, Núm. 8, pp. 1509-1525

2023

  1. TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory

    Cancer Cell, Vol. 41, Núm. 11, pp. 1911-1926.e8

2022

  1. Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas

    JCI Insight, Vol. 7, Núm. 7

  2. Galectin-3 inhibition boosts the therapeutic efficacy of Semliki Forest virus in pediatric osteosarcoma

    Molecular Therapy - Oncolytics, Vol. 26, pp. 246-264

  3. Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory

    Molecular Cancer Therapeutics, Vol. 21, Núm. 3, pp. 471-480

  4. Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma

    New England Journal of Medicine, Vol. 386, Núm. 26, pp. 2471-2481

2021

  1. CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 7

  2. Clinical value of NGS genomic studies for clinical management of pediatric and young adult bone sarcomas

    Cancers, Vol. 13, Núm. 21

  3. Delta-24-RGD, an oncolytic adenovirus, increases survival and promotes proinflammatory immune landscape remodeling in models of AT/RT and CNS-PNET

    Clinical Cancer Research, Vol. 27, Núm. 6, pp. 1807-1820

  4. Local administration of IL-12 with an HC vector results in local and metastatic tumor control in pediatric osteosarcoma

    Molecular Therapy - Oncolytics, Vol. 20, pp. 23-33

2020

  1. Sarcoma treatment in the era of molecular medicine

    EMBO Molecular Medicine, Vol. 12, Núm. 11

2019

  1. The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models

    Nature Communications, Vol. 10, Núm. 1

2018

  1. Assessment of metabolic patterns and new antitumoral treatment in osteosarcoma xenograft models by [ 18 F]FDG and sodium [ 18 F]fluoride PET

    BMC Cancer, Vol. 18, Núm. 1

2017

  1. Doxorubicin and edelfosine lipid nanoparticles are effective acting synergistically against drug-resistant osteosarcoma cancer cells

    Cancer Letters, Vol. 388, pp. 262-268

2016

  1. Matrix-Gla protein promotes osteosarcoma lung metastasis and associates with poor prognosis

    Journal of Pathology, Vol. 239, Núm. 4, pp. 438-449

  2. The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma

    Clinical Cancer Research, Vol. 22, Núm. 9, pp. 2217-2225

2015

  1. Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner

    Cancer Letters, Vol. 368, Núm. 1, pp. 54-63

  2. Lipid nanoparticles enhance the efficacy of chemotherapy in primary and metastatic human osteosarcoma cells

    Journal of Drug Delivery Science and Technology, Vol. 30, pp. 435-442

2014

  1. The oncolytic adenovirus Δ24-RGD in combination with cisplatin exerts a potent anti-osteosarcoma activity

    Journal of Bone and Mineral Research, Vol. 29, Núm. 10, pp. 2287-2296

2013

  1. Erratum: ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia (Oncogene (2013) 32 (803) DOI: 10.1038/onc.2012.593)

    Oncogene